2007
Aripiprazole in the treatment of the psychosis prodrome
Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, Mathalon DH, Miller TJ, McGlashan TH. Aripiprazole in the treatment of the psychosis prodrome. The British Journal Of Psychiatry. Supplement 2007, 191: s96-s101. PMID: 18055946, DOI: 10.1192/bjp.191.51.s96.Peer-Reviewed Original ResearchConceptsPsychosis prodromeMixed-effects repeated-measures analysisShort-term efficacySymptom total scoreSingle-site trialRepeated-measures analysisAripiprazole treatmentAdverse eventsFinal visitSafety profilePromising efficacyProdromal phasePsychotic disordersScale scoreBaseline levelsWeight gainFirst weekProdromeTotal scoreAripiprazoleTreatmentNeuropsychological measuresPreliminary evidenceWeeksEfficacy
2003
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome
Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry 2003, 54: 453-464. PMID: 12915290, DOI: 10.1016/s0006-3223(03)00321-4.Peer-Reviewed Original ResearchConceptsExtrapyramidal symptomsPlacebo-controlled trialShort-term efficacyTrial of olanzapineTreatment x time interactionGreater symptomatic improvementSymptom total scoreX time interactionGreater weight gainRepeated-measures analysisOlanzapine patientsSchizophrenic prodromeOlanzapine treatmentPlacebo patientsSymptomatic improvementAcute treatmentMore patientsOlanzapine 5Prodromal symptomsRoutine treatmentProdromal patientsProdromal phaseWeek 8Week 6Placebo